KKPCF Stock - Kaken Pharmaceutical Co., Ltd.
Unlock GoAI Insights for KKPCF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $94.03B | $72.04B | $72.98B | $76.03B | $74.98B |
| Gross Profit | $58.53B | $38.54B | $39.56B | $41.58B | $40.91B |
| Gross Margin | 62.2% | 53.5% | 54.2% | 54.7% | 54.6% |
| Operating Income | $21.03B | $9.51B | $8.00B | $17.06B | $17.79B |
| Net Income | $13.95B | $8.03B | $5.44B | $9.55B | $13.40B |
| Net Margin | 14.8% | 11.1% | 7.5% | 12.6% | 17.9% |
| EPS | $365.42 | $212.66 | $144.79 | $251.44 | $347.37 |
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation. The company also provides Adofeed, a pain- and inflammation-relieving plaster; Ebrantil for the treatment of dysuria and hypertension; Procylin, an oral-use prostaglandin I2 analog; Lipidil, an anti-hyperlipidemia agent; Mentax, an anti-trichophyton agent; and Loxoprofen Na Tape, a pain-relieving and anti-inflammatory plaster. In addition, it offers Ropion, a pain relief injection; and agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone, a rice herbicide; and Salinomycin, an anti-coccidial feed additive for chicken. Further, the company is developing BBI-4000 that has completed phase III clinical trial for primary axillary hyperhidrosis; KMW-1, which is in phase III clinical trial for the removal of eschar with thermal burns; KAR for treatment of hide lice infestation; and KP-607, which is in phase II clinical trial for the treatment of onychomycosis. Additionally, it is involved in the rental of Bunkyo Green Court, a commercial complex. The company offers its products under the Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia brands. It has license agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.
Visit WebsiteEarnings History & Surprises
KKPCFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 5, 2026 | — | — | — | — |
Q4 2025 | Nov 10, 2025 | — | $0.00 | — | — |
Q3 2025 | Aug 7, 2025 | — | $0.05 | — | — |
Q2 2025 | May 12, 2025 | — | $-0.92 | — | — |
Q1 2025 | Feb 4, 2025 | — | $0.82 | — | — |
Q4 2024 | Nov 8, 2024 | — | $2.30 | — | — |
Q3 2024 | Aug 7, 2024 | — | $0.29 | — | — |
Q2 2024 | May 14, 2024 | — | $0.23 | — | — |
Q1 2024 | Feb 6, 2024 | — | $0.49 | — | — |
Q3 2023 | Sep 30, 2023 | — | $0.28 | — | — |
Q2 2023 | Jun 30, 2023 | — | $0.46 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.75 | — | — |
Q1 2023 | Feb 2, 2023 | — | $85.00 | — | — |
Q4 2022 | Nov 7, 2022 | — | $81.46 | — | — |
Q3 2022 | Aug 3, 2022 | — | $76.89 | — | — |
Q2 2022 | May 11, 2022 | — | $-18.43 | — | — |
Q1 2022 | Feb 2, 2022 | — | $93.18 | — | — |
Q4 2021 | Nov 4, 2021 | — | $88.47 | — | — |
Q3 2021 | Aug 3, 2021 | — | $87.76 | — | — |
Latest News
Frequently Asked Questions about KKPCF
What is KKPCF's current stock price?
What is the analyst price target for KKPCF?
What sector is Kaken Pharmaceutical Co., Ltd. in?
What is KKPCF's market cap?
Does KKPCF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to KKPCF for comparison